Actelion to present at the 31st Annual J.P. Morgan Healthcare Conference - Delivering on our strategy
* Reuters is not responsible for the content in this press release.
For best results when printing this announcement, please click on the link below: http://pdf.reuters.com/htmlnews/8knews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130107:nHUGcS2f Actelion Pharmaceuticals Ltd / Actelion to present at the 31st Annual J.P. Morgan Healthcare Conference - Delivering on our strategy . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ALLSCHWIL/BASEL, SWITZERLAND - 07 January 2013- Actelion Ltd (SIX: ATLN) Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, M.D., Chief Executive Officer of Actelion, will present at the J. P. Morgan Healthcare Conference on Tuesday, 08 January 2013 at 9.30 a.m. Pacific time / 18.30 hrs Swiss time at the Westin St. Francis Hotel in San Francisco, CA. Dr. Clozel will describe the progress made during 2012 in delivering on the three elements of Actelion's strategy for value creation. 1) Sustain and grow the PAH franchise Dr. Clozel will present an overview of Actelion's current product offerings in the pulmonary arterial hypertension (PAH) market. He will also describe the excellent morbidity / mortality outcome data from the SERAPHIN study with macitentan (Opsumit(R)). This novel and differentiated dual endothelin receptor antagonist (ERA) was the result of a tailored drug discovery process in Actelion's labs. In addition, Dr. Clozel will describe the opportunity for the Company's selective IP receptor agonist, selexipag - developed together with Nippon Shinyaku - which has now enrolled over 1,000 patients into GRIPHON, a pivotal study also designed to demonstrate a reduction in the risk of morbidity/mortality events. Dr. Clozel will present how Actelion's franchise today and in the future has the potential to reshape the treatment paradigm in PAH. 2) Build an additional specialty franchise Dr. Clozel will also present the positive results with the Company's innovative compounds, ponesimod in psoriasis and cadazolid in Clostridium difficile associated diarrhea. At the end of 2012, mid-stage clinical studies reported results that allowed Actelion to decide to pursue both compounds in Phase III development. This provides Actelion with the foundation for its mid-term goal of building an additional specialty franchise. 3) Optimize profitability As the third element to Actelion's strategy, the company is committed to profit growth in the coming years and to value creation for shareholders. Dr. Clozel will present the measures taken to ensure the company can deliver on these commitments and the company's near and mid-term core earnings guidance. Jean-Paul Clozel, MD and Chief Executive Officer of Actelion commented: "At last year's J. P. Morgan conference I told the audience that 2012 would be an important year for Actelion. I am very pleased to take this opportunity to describe the excellent progress the company has made to deliver on our strategy for value creation. In 2013, and the years to come, Actelion will realize the value it has created from innovation in our labs." The presentation is available in pdf-format on www.actelion.com http://www.actelion.com/ . To access the live and subsequently archived webcast of the presentation, visit "Events" in the Investor Relations section of Actelion's corporate website. An archived replay will be available for 3 months beginning 24 hours after the live presentation. ### Actelion Ltd. Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer(R), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer(R) through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,400 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI(R)). For further information please contact: Roland Haefeli Senior Vice President, Head of Investor Relations & Public Affairs Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil +41 61 565 62 62 +1 650 624 69 36 www.actelion.com http://www.actelion.com/ The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Press Release PDF http://hugin.info/131801/R/1668485/541764.pdf ---------------------------------------------------------------------------------------------------- This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Actelion Pharmaceuticals Ltd via Thomson Reuters ONE HUG#1668485 --- End of Message --- Actelion Pharmaceuticals Ltd Gewerbestrasse 16 Allschwil Switzerland ISIN: CH0010532478;